$67.690
-2.180 (-3.22%)Zum Schluss
LQDA-News
LQDA-Events
Liquidia Reports Q2 Revenue of $171.68M, Exceeds Expectations
Reports Q2 revenue $171.68M, consensus $168.48M. Roger Jeffs, Liquidia's CEO, said: "We are pleased by the sustained adoption of YUTREPIA as the inhaled prostacyclin of choice. The inhaled category has grown almost 40% since launch, and YUTREPIA has captured an ever-increasing share of that growth. We are building on that momentum by strengthening the clinical evidence for YUTREPIA in PAH and PH-ILD patients transitioning from other therapies, and advancing studies in new indications that may broaden its impact. Having reset the bar for tolerability and dose flexibility with YUTREPIA, we are excited to have begun site activation and enrollment in Re-Spire, our pivotal study for L606, which we believe can raise that bar even further, beyond any therapy currently available or in development."
Liquidia Shares Rise 17.6% to $65.50
Liquidia is up 17.6%, or $9.81 to $65.50.
Major Averages Close Slightly Higher as Investors Focus on Economic Data
The major averages closed slightly higher despite a continued stalemate in U.S.-Iran negotiations and continued disruption around the Strait of Hormuz. Markets begin the week in the green as they look to build on six straight weeks of gains, with investors trying to reconcile resilient economic data, rising geopolitical risk and an AI trade that refuses to cool off.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:FoxreportedCircle Internetreportedand provided FY26 guidanceDream Finders HomesBeazer Homesfor $25.75 per shareMosaicreported, lowered its FY26 CapEx guidance, and withdrew its FY26 phosphate production guidancePresident Trump is set to travel to China this week,including Tesla'sElon Musk and Apple'sTim Cook2. WALL STREET CALLS:UBSDell Technologieson valuation after rallyUberto Outperform at Fox Advisors as investments start paying offWendy'sto Underweight at JPMorganStarz Entertainmentto Outperform at BairdWall Streeton two recent IPOs, Madison Airand Arxis3. AROUND THE WEB:Starbucksplans to lay off 61 corporate staff in its technology unit at its Seattle headquarters, Reuters reportsApollo Globalis in talks to sell MidCap Financial, WSJ reportsA Microsoftdata center site in East Africa has been delayed due to disagreements with the Kenyan government over guaranteed payments, Bloomberg reportsGeneral Motorswill pay $12.75M to resolve a California investigation into claims that it illegally sold the location and driving data of OnStar subscribers to brokers, Reuters saysAppleis working on a "slight redesign" for macOS 27 to address Liquid Glass issues, Bloomberg says4. MOVERS:Babcock & Wilcoxrises afterMonday.comhigher afterand providing guidance for Q2 and FY26Erascagains after entering into anand supply agreement with MerckCertarafalls afterTelephone & Data Systemslower after Raymond Jamesthe stock to Market Perform from Outperform5. EARNINGS/GUIDANCE:Seadrillprovided areport for Q1Townsquare MediareportedDolereported ain Q1 earningsKodiak Gas Servicesprovided areport for Q1LiquidiareportedINDEXES:The Dow rose 95.31, or 0.19%, to 49,704.47, the Nasdaq gained 27.05, or 0.10%, to 26,274.13, and the S&P 500 advanced 13.91, or 0.19%, to 7,412.84.
Major Averages Slightly Higher as Investors Eye Geopolitical Risks
The major averages were slightly higher near noon despite another deterioration in U.S.-Iran negotiations and continued disruption around the Strait of Hormuz. Markets are starting off in the green after six straight weeks of gains, with investors trying to reconcile resilient economic data, rising geopolitical risk and an AI trade that refuses to cool off.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:FoxreportedCircle Internetreportedand provided FY26 guidanceDream Finders HomesBeazer Homesfor $25.75 per shareMosaicreported, lowered its FY26 CapEx guidance, andd withdrew its FY26 phosphate production guidanceSeadrillprovided areport for Q12. WALL STREET CALLS:UBSDell Technologieson valuation after rallyUberto Outperform at Fox Advisors as investments start paying offWendy'sto Underweight at JPMorganStarz Entertainmentto Outperform at BairdWall Streeton two recent IPOs, Madison Airand Arxis3. AROUND THE WEB:Apollo Globalis in talks to sell MidCap Financial, WSJ reportsA Microsoftdata center site in East Africa has been delayed due to disagreements with the Kenyan government over guaranteed payments, Bloomberg reportsGeneral Motorswill pay $12.75M to resolve a California investigation into claims that it illegally sold the location and driving data of OnStar subscribers to brokers, Reuters saysAppleis working on a "slight redesign" for macOS 27 to address Liquid Glass issues, Bloomberg saysA Frontier Airlinesplane hit and killed a trespasser who breached airport security and ran out onto a runway at Denver International airport late on Friday, WSJ says4. MOVERS:Babcock & Wilcoxrises afterMonday.comhigher after reportingand providing guidance for Q2 and FY26Erascagains after entering into an AURORAS-1 clinical trial andCertarafalls afterTelephone & Data Systemslower after Raymond Jamesthe stock to Market Perform from Outperform5. EARNINGS/GUIDANCE:Townsquare MediareportedDolereported ain Q1 earningsKodiak Gas Servicesprovided areport for Q1LiquidiareportedAgenusreported ain Q1 revenueINDEXES:Near midday, the Dow was flat at 49,610.87, the Nasdaq was up 0.33%, or 87.72, to 26,334.80, and the S&P 500 was up 0.33%, or 24.13, to 7,423.06.
YUTREPIA Reports Q1 Revenue of $129.9M
Reports Q1 revenue $129.9M, consensus $119.4M. Cash and cash equivalents totaled $222.8M as of March 31, 2026, vs. $190.7M as of December 31, 2025. CEO Roger Jeffs said: "In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.